Hematology AdvisorTrump Administration’s CDC Cuts Threaten Safety and Progress in Blood Disorders

The Trump administration’s elimination of the CDC’s Division of Blood Disorders and Public Health Genomics on April 1, 2025, threatens critical surveillance programs and patient resources for blood disorders. This division managed essential programs including the Sickle Cell Data Collection program covering 16 states and more than half of US patients with sickle cell disease.

⚕️Key Clinical Considerations⚕️

• Data Collection Disruption: The Sickle Cell Data Collection program, which tracked outcomes for more than 50% of US patients with SCD across 16 states, faces termination, eliminating crucial epidemiological surveillance capabilities.
• Resource Gap Creation: Elimination of patient and provider educational resources creates immediate information gaps that could worsen health disparities for patients with inherited blood disorders requiring specialized care coordination.
• Treatment Center Impact: Hemophilia treatment centers providing specialized multidisciplinary care for bleeding disorders may lose federal coordination and support, potentially fragmenting care delivery networks.
• Blood Safety Monitoring: Loss of blood product safety surveillance capabilities that originated from the 1980s HIV/hepatitis C crisis when 90% of hemophilia patients were infected through contaminated clotting factors.
• Research Program Termination: Discontinuation of ongoing research initiatives and data collection efforts that inform evidence-based treatment protocols and resource allocation decisions for rare blood disorders.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Clinicians must proactively inform patients with blood disorders about potential service disruptions and maintain updated resource lists as federal programs wind down.
• Practice Integration: Hematology practices should establish direct relationships with patient advocacy organizations and state health departments to maintain care coordination previously facilitated by CDC programs.
• Risk Management: Providers treating hemophilia and other bleeding disorders need contingency plans for accessing specialized resources and maintaining quality metrics without federal program support.
• Action Items: Clinicians should engage with professional organizations like ASH’s #Fight4Hematology Action Hub to advocate for program restoration while developing alternative data collection and patient support mechanisms.

More in Hematology